Oncology research and precision drug development by Tyra Biosciences

  • Pavlo Kot
  • 12 hours ago
Tyra Biosciences initiates Phase 2 SURF302 trial for oral FGFR3-selective inhibitor in NMIBC
Tyra Biosciences has begun its Phase 2 SURF302 study, investigating an oral FGFR3-selective inhibitor as a potential treatment for low-grade intermediate-risk non-muscle invasive bladder cancer ...
  • Yulia Slavina
  • 02.11.2026
Tyra Biosciences publishes new research on FGFR3-selective inhibitors for urologic cancers and achondroplasia
Tyra Biosciences announced the publication of a new scientific paper in the Journal of Medicinal Chemistry examining the biology, molecular design, and therapeutic implications of FGFR3-selective ...
  • Elena Nikulina
  • 19.10.2026
Tyra Biosciences advances research on FGFR3-driven treatment strategies
Tyra Biosciences is working to develop new therapies targeting the FGFR3 biological pathway, with a focus on treating achondroplasia and certain urologic cancers. FGFR3 serves as a shared ...
  • Oksana Koneva
  • 25.09.2026
Tyra Biosciences reports initial Phase 2 SURF302 results in dabogratinib bladder cancer trial
Tyra Biosciences announced the initial Phase 2 results from its SURF302 clinical study, which evaluates dabogratinib for the treatment of bladder cancer. The company noted that the September 9 ...
  • Oleksii Zaichenko
  • 02.09.2026
Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat
Tyra Biosciences attracted industry attention during the IBCG26 Annual Retreat, where the company engaged with attendees over new developments shaping the future of bladder cancer treatment. The ...
  • Andreas Kristo
  • 24.08.2026
Tyra Biosciences pursues new FGFR3 inhibitor for achondroplasia treatment in BEACH301 study
Tyra Biosciences is evaluating a potential new treatment for achondroplasia through its BEACH301 clinical study. The company is focusing on selective FGFR3 inhibition to support improved ...
  • Artem Shendetskii
  • 18.08.2026
Tyra Biosciences tests innovative therapy in SURF302 for intermediate-risk bladder cancer
Tyra Biosciences has launched the SURF302 clinical trial to assess a novel therapeutic strategy targeting intermediate-risk non-muscle invasive bladder cancer (IR-NMIBC). The study aims to ...
  • Andrey Mastykin
  • 14.08.2026
Tyra Biosciences examines FGFR3 gene impact on cell growth disorders
Tyra Biosciences reports that the FGFR3 gene plays a critical role in regulating cell growth and bone development. The company indicates that alterations in FGFR3 signaling can contribute to ...
  • Eugene Komchuk
  • 24.07.2026
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
Tyra Biosciences has initiated the SURF302 study, focusing on an investigational oral therapeutic approach for patients with non-muscle invasive bladder cancer (NMIBC). The company aims to ...
  • Jose Antonio Gastelum
  • 22.07.2026
Tyra Biosciences pursues new treatment strategies for urologic cancers
Tyra Biosciences is intensifying efforts to advance novel treatment approaches for individuals living with urologic cancers, including IR-NMIBC and LG-UTUC. The company announced its intention ...